Journal Article

MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)

Guckenberger, M., Belka, C., Debus, J., Mayerle, J., Corradini, S., Vornhülz, M., Mansmann, U., Niyazi, M., Fritsch, R., Wilke, L., Hörner-Rieber, J., Al Tawil, A., Pavic, M., Beyer, G.

2022

Overview

Background Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy is a well-established local treatment option but there is some evidence for a better and longer pain response after a dose-intensified radiotherapy of the primary pancreatic cancer (pPCa). Stereotactic body radiation therapy (SBRT) can deliver high radiation doses in few fractions, therefore reducing chemotherapy-free intervals. However, prospective data on pain control after SBRT of pPCa is very limited. Therefore, we aim to investigate the impact of SBRT on pain control in patients with mPDAC in a prospective trial. Methods This is a prospective, double-arm, randomized controlled, international multicenter study testing the added benefit of MR-guided adaptive SBRT of the pPca embedded between standard of care-chemotherapy (SoC-CT) cycles for pain control and prevention of pain in patients with mPDAC. 92 patients with histologically proven mPDAC and at least stable disease after initial 8 weeks of SoC-CT will be eligible for the trial and 1:1 randomized in 3 centers in Germany and Switzerland to either experimental arm A, receiving MR-guided SBRT of the pPCa with 5 × 6.6 Gy at 80% isodose with continuation of SoC-CT thereafter, or control arm B, continuing SoC-CT without SBRT. Daily MR-guided plan adaptation intents to achieve good target coverage, while simultaneously minimizing dose to organs at risk. Patients will be followed up for minimum 6 and maximum of 18 months. The primary endpoint of the study is the “mean cumulative pain index” rated every 4 weeks until death or end of study using numeric rating scale. Discussion An adequate long-term control of pain symptoms in patients with mPDAC is an unmet clinical need. Despite improvements in systemic treatment, local complications due to pPCa remain a clinical challenge. We hypothesize that patients with mPDAC will benefit from a local treatment of the pPCa by MR-guided SBRT in terms of a durable pain control with a simultaneously favorable safe toxicity profile translating into an improvement of quality-of-life. Trial registration German Registry for Clinical Trials (DRKS): DRKS00025801. Meanwhile the study is also registered at ClinicalTrials.gov with the Identifier: NCT05114213.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Adaptive control / Adenocarcinoma / Adenocarcinoma - radiotherapy / Adenocarcinoma - secondary / Biomedical and Life Sciences / Biomedicine / Cancer Pain - radiotherapy / Cancer Research / Cancer therapies / Chemotherapy / Clinical Radiation Oncology / Clinical trials / Complications / Health services / Humans / Imaging / Magnetic Resonance Imaging / Metastases / Metastasis / Metastasized / MR-guided radiotherapy / Oncology / Pain / Pain control / Pancreatic cancer / Pancreatic Neoplasms - pathology / Pancreatic Neoplasms - radiotherapy / Patients / Prospective Studies / Quality of life / Radiation / Radiation dosage / Radiation therapy / Radiology / Radiosurgery - methods / Radiotherapy / Radiotherapy, Image-Guided / Response rates / SBRT / Signs and symptoms / Stereotactic body radiotherapy / Study Protocol / Systematic review / Toxicity / Tumors